Figure 1: Non-cabg-related Timi Major Or Minor Bleeding Events. (Prasugrel Fig1)
Prasugrel Tablet, Film Coated
Product Images NDC 65862-829
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Prasugrel (NDC 65862-829). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Aurobindo Pharma Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 2: Inhibition (mean±sd) Of 20 μm Adp-induced Platelet Aggregation (ipa) Measured By Light Transmission Aggregometry After Prasugrel 60 mg. (Prasugrel Fig2)
Figure 3: Time To First Event Of Cv Death, Mi, Or Stroke (triton-timi 38). (Prasugrel Fig3)
This appears to be a table or graph related to the percentage of cardiovascular death, nonfatal MI, or nonfatal stroke in a study. The table includes different medications such as Clopidogrel and Prasugrel and mentions "UANSTEMI" which could be related to a medical condition. Not enough context is provided to give a more detailed description of the study or its results.*
Figure 4: Subgroup Analyses For Time To First Event Of Cv Death, Mi, Or Stroke (hr And 95% Ci; Triton-timi 38) – Ua/nstemi Patients. (Prasugrel Fig4)
This is a table showing the baseline characteristics of patients involved in a study comparing Prasugrel and Clopidogrel. The characteristics assessed include age, gender, body weight, region, diabetes mellitus, metabolic syndrome, previous medical history, and stent type. The table also shows the percentage of events in each category for both Prasugrel and Clopidogrel groups.*
Figure5 (Prasugrel Fig5)
This appears to be a statistical report comparing the characteristics of patients who were administered Prasugrel versus Clopidogrel for the treatment of STEMI (ST-segment elevation myocardial infarction). The report includes details such as the patient's age, weight, gender, and medical history of diabetes and previous surgeries. The report also includes the use of GP lib/lla Inhibitor - a medication that helps prevent blood clots. The data is presented in tables and includes a comparison of hazard ratios for the two medications.*
Package Label-principal Display Panel (5 mg (30 Tablets Bottle))
Each tablet is a film-coated Prasugrel hydrochloride 5.49 mg, distributed by Aurobindo Pharma USA Inc. The usual dosage should be seen in the package insert. Store it between 20-25°C (68-77°F) and keep it in the original container. Dispense it with the medication guide provided separately for each patient. The bottle has a desiccant, and it must not be used if the inner seal is missing or broken.*
Package Label-principal Display Panel (5 mg (3 x 10) Unit-dose Tablets)
Prasugrel Tablets are available in a 30-unit dose package. Each film-coated tablet contains 5mg of Prasugrel, and the usual dosage can be seen in the accompanying package. These tablets should be stored at controlled room temperature and kept away from children. The package is not child-resistant, so if dispensed for outpatient use, a child-resistant container should be used. Information about the manufacturer and the drug's code is also mentioned.*
Package Label-principal Display Panel (10 mg (30 Tablets Bottle))
This is a description for Prasugrel Tablets, with each film-coated tablet containing Prasugrel hydrochloride 10.98 mg, equivalent to prasugrel 10 mg. The typical dosage would be found in the accompanying package insert. It is important to store these tablets at room temperature and inside their original container, with the desiccant, between 20°-25°C (68°-77°F). Dispensing the medication guide for each patient is recommended, and it is not for use if the inner seal is missing or broken. Distributed by Aurabindo Pharma USA, Inc. and made in India, the package code is TSDRUGS22/2009.*
Package Label-principal Display Panel (10 mg (3 x 10) Unit-dose Tablets)
This is a description for Prasugrel hydrochloride tablets, which come in a package of 30 unit-dose tablets. Each tablet contains 10mg of Prasugrel hydrochloride. The usual dosage is provided in the accompanying package insert. The tablets should be stored at controlled room temperature, away from children. The package is not child-resistant and a child-resistant container should be used if dispensed for outpatient use. The tablets are distributed by Aurobindo Pharma USA, Inc. and made in India.*
Chemical Structure (Prasugrel Str)
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
